Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 4 | 5 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 7 | 2 |
| 2 Introduction | 9 | 1 |
| 2.1 GBI Research Report Guidance | 9 | 1 |
| 3 The Future of Biosimilars Market Overview | 10 | 7 |
| Overview of the Biopharmaceutical Industry | 10 | 3 |
| 3.2 Comparison of Biosimilars with Generics | 13 | 1 |
| 3.3 Biopharmaceutical Manufacturing Process | 14 | 3 |
| 4 The Future of Biosimilars Market Characterization | 17 | 16 |
| 4.1 Global Biosimilars Market Size and Forecasts | 17 | 1 |
| The US Biosimilars Market Size and Forecasts | 18 | 1 |
| 4.3 Europe Biosimilars Market Size and Forecasts | 18 | 1 |
| 4.4 Japan Biosimilars Size and Market Forecasts | 19 | 1 |
| 4.5 Market Forecasts for Biosimilars | 20 | 1 |
| 4.5.1 Human Growth Hormone Biosimilars Markets | 20 | 2 |
| 4.5.2 Erythropoietin (EPO) Biosimilars Markets | 22 | 1 |
| 4.5.3 Granulocyte Colony Stimulating Factor (G-CSF) Biosimilars Markets | 23 | 2 |
| 4.6 Opportunity Analysis | 25 | 1 |
| 4.6.1 Interferon-alpha Biosimilars | 25 | 1 |
| 4.6.2 Interferon-beta Biosimilars | 26 | 2 |
| Insulin and Insulin Analogs Biosimilars | 28 | 2 |
| 4.6.4 Monoclonal Antibodies | 30 | 1 |
| 4.7 Unmet Needs in the Biopharmaceutical Market | 30 | 3 |
| 5 The Future of Biosimilars Regulatory Landscape | 33 | 32 |
| 5.1 Regulatory Landscape in the US | 33 | 1 |
| 5.1.1 Regulatory Framework for Biopharmaceutical Industry | 33 | 2 |
| 5.1.2 Evolution of Regulatory Pathways for Biosimilars | 35 | 2 |
| 5.1.3 Current Position on Biosimilars | 37 | 1 |
| 5.1.3.1 Comparison of the Eshoo Barton and the Waxman Legislative Proposals | 37 | 5 |
| 5.1.3.2 Approval of Omnitrope | 42 | 1 |
| 5.1.4 Drivers and Barriers | 42 | 1 |
| 5.2 Regulatory Landscape in Europe | 43 | 1 |
| 5.2.1 Regulatory Framework for Biopharmaceutical Industry | 43 | 1 |
| 5.2.2 Evolution of Regulatory Pathways for Biosimilars | 44 | 1 |
| 5.2.3 Current Position on Biosimilars | 45 | 1 |
| 5.2.3.1 Overarching Guidelines | 46 | 1 |
| 5.2.3.2 Quality Guidelines | 46 | 1 |
| 5.2.3.3 Non-Clinical and Clinical Guidelines | 47 | 1 |
| 5.2.3.4 Annexes Product Specific Guidelines | 47 | 1 |
| 5.2.3.5 Post-Authorization Requirements | 47 | 1 |
| 5.2.3.6 Data Exclusivity Period | 48 | 1 |
| 5.2.3.7 What Does this Mean to the Biosimilar Industry? | 49 | 1 |
| 5.2.4 The Bolar Type Provision | 49 | 1 |
| 5.2.5 The Comparability Exercise | 50 | 1 |
| 5.2.6 Biosimilars Approvals and Applications | 51 | 2 |
| 5.2.7 Issues Facing the European Biosimilars Industry | 53 | 1 |
| 5.2.7.1 Naming | 53 | 1 |
| 5.2.7.2 Labeling | 53 | 1 |
| 5.2.7.3 Substitution / Interchangeability | 53 | 1 |
| 5.2.7.4 Pharmacovigilance | 54 | 1 |
| 5.2.8 Drivers for the European Biosimilars Market | 54 | 1 |
| 5.2.8.1 Patent Expiry of Key Biologic Drugs Will Boost the Market Potential | 54 | 1 |
| 5.2.8.2 Biosimilars Will be Widely accepted by Payers as a Means to Reduce Rising Healthcare Costs | 54 | 1 |
| 5.2.8.3 Leading Pharmaceutical Companies Eye Biosimilars as an Area of Growth | 55 | 1 |
| 5.2.8.4 Biosimilar Manufacturers From Low Cost Emerging Countries Will Drive Market Expansion | 55 | 1 |
| 5.2.9 Barriers for the European Biosimilars Market | 55 | 1 |
| 5.2.9.1 Substitution Remains a Contentious Issue in Many European Countries | 55 | 1 |
| 5.2.9.2 Barriers to Entry Remain High Due to a Complex and High Cost Manufacturing Process | 55 | 1 |
| 5.2.9.3 Tradeoff Between Patient Safety and Healthcare Costs Will Resist the Acceptance of Biosimilars | 55 | 1 |
| 5.2.10 Country Analysis - The United Kingdom | 55 | 1 |
| 5.2.10.1 Structure of the Healthcare System | 55 | 1 |
| 5.2.10.2 Pricing and Reimbursement Mechanisms | 56 | 1 |
| 5.2.10.3 Drivers and Barriers for Biosimilars | 56 | 1 |
| 5.2.11 Country Analysis - Germany | 56 | 1 |
| 5.2.11.1 Structure of the Healthcare System | 56 | 1 |
| 5.2.11.2 Pricing and Reimbursement Mechanisms | 57 | 1 |
| 5.2.11.3 Drivers and Barriers for Biosimilars | 57 | 1 |
| 5.2.12 Country Analysis - France | 58 | 1 |
| 5.2.12.1 Structure of the Healthcare System | 58 | 1 |
| 5.2.12.2 Pricing and Reimbursement Mechanisms | 58 | 1 |
| 5.2.12.3 Drivers and Barriers for Biosimilars | 59 | 1 |
| 5.2.13 Country Analysis - Spain | 59 | 1 |
| 5.2.13.1 Structure of the Healthcare System | 59 | 1 |
| 5.2.13.2 Pricing and Reimbursement Mechanisms | 59 | 1 |
| 5.2.13.3 Drivers and Barriers for Biosimilars | 60 | 1 |
| 5.2.14 Country Analysis - Italy | 61 | 1 |
| 5.2.14.1 Structure of the Healthcare System | 61 | 1 |
| 5.2.14.2 Pricing and Reimbursement Mechanisms | 61 | 1 |
| 5.2.14.3 Drivers and Barriers for Biosimilars | 61 | 1 |
| 5.3 The Regulatory Landscape in Japan | 62 | 1 |
| 5.3.1 The Regulatory Framework for the Biopharmaceutical Industry | 62 | 1 |
| 5.3.2 Evolution of Regulatory Pathways for Biosimilars | 63 | 1 |
| 5.3.3 Current Position on Biosimilars | 63 | 1 |
| 5.3.3.1 The First Biosimilar Approved | 64 | 1 |
| 5.3.4 Drivers and Barriers | 64 | 1 |
| The Future of Biosimilars Competitive Landscape | 65 | 27 |
| 6.1 The Costs of Biosimilar Development Are Higher Than That of Generics | 65 | 1 |
| 6.2 High Initial Investments Favors Growth of Biosimilars Players with Financial Strength | 66 | 1 |
| 6.3 Technical Expertise in Biopharmaceutical Development and Manufacturing Determines Strategic Positioning | 67 | 2 |
| 6.4 Leading Biosimilars Players | 69 | 1 |
| 6.4.1 Teva Pharmaceuticals Ltd | 69 | 1 |
| 6.4.1.1 Approved Biosimilars | 70 | 1 |
| Dr. Reddy s Laboratories | 71 | 1 |
| 6.4.2.1 Approved Biosimilars | 71 | 1 |
| 6.4.3 Phage Biotechnology Corporation | 72 | 1 |
| 6.4.3.1 Pipeline | 73 | 1 |
| 6.4.4 Cangene Corporation | 73 | 2 |
| 6.4.5 Biopartners | 75 | 1 |
| 6.4.5.1 Approved Biosimilars | 75 | 1 |
| Pipeline | 76 | 1 |
| 6.4.6 BioCon Ltd | 76 | 1 |
| 6.4.6.1 Approved Biosimilars | 77 | 1 |
| 6.4.7 BioGenerix AG | 78 | 1 |
| 6.4.7.1 Pipeline | 78 | 1 |
| 6.4.8 Apotex Inc | 79 | 1 |
| Sandoz | 80 | 1 |
| 6.4.9.1 Approved Biosimilar Products | 81 | 1 |
| 6.4.10 Hospira Inc | 82 | 1 |
| 6.4.10.1 Approved Biosimilar Products | 82 | 1 |
| 6.4.11 Watson Pharmaceuticals | 83 | 1 |
| STADA Arzneimittel AG | 84 | 1 |
| 6.4.13 ANALIZA, INC | 85 | 1 |
| 6.4.14 Reliance GeneMedix Plc | 86 | 1 |
| 6.4.14.1 Approved Biosimilar Products | 87 | 1 |
| Momenta Pharmaceuticals | 88 | 1 |
| 6.4.15.1 Pipeline | 88 | 1 |
| 6.4.16 Microbix Biosystems Inc | 89 | 1 |
| 6.4.17 Dragon Pharmaceuticals | 90 | 2 |
| The Future of Biosimilars Strategic Consolidations | 92 | 2 |
| 7.1 Mergers &Acquisitions | 92 | 1 |
| 7.1.1 Merck Acquires Insmed s Follow-On Biologics for $130m | 92 | 1 |
| 7.1.2 Teva and Lonza Joint Venture Targets Biosimilars | 92 | 1 |
| 7.1.3 GTC Enters a Follow-On-Biologic Founder Development Collaboration With Ag Research | 92 | 1 |
| 7.2 Licensing Deals | 92 | 1 |
| 7.2.1 Innogene Seals Deal With CIMAB To Market Biosimilars | 92 | 1 |
| 7.2.2 Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon | 93 | 1 |
| 8 Appendix | 94 | 4 |
| 8.1 Market Definitions | 94 | 1 |
| 8.2 Abbreviations | 94 | 1 |
| 8.3 Research Methodology | 95 | 3 |
| 8.3.1 Coverage | 96 | 1 |
| 8.3.2 Secondary Research | 96 | 1 |
| 8.3.3 Primary Research | 97 | 1 |
| 8.3.4 Expert Panel Validation | 97 | 1 |
| 8.4 Contact Us | 97 | 1 |
| 8.5 Disclaimer | 97 | 1 |